Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Iovance Biotherapeutics, Inc.    IOVA

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

IOVANCE BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/04/2019 | 04:15pm EST

Item 2.02. Results of Operations and Financial Condition.

On November 4, 2019, Iovance Biotherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2019 and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1.

The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.

Item 9.01. Financial Statements and Exhibits.





(d)    Exhibits.



Exhibit No.                               Description
   99.1         Press Release of Iovance Biotherapeutics, Inc., dated November 4,
              2019.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IOVANCE BIOTHERAPEUTICS, I
12/02Iovance Biotherapeutics to Present at Upcoming Investor Conferences in Decemb..
GL
11/21Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients ..
GL
11/12IOVANCE BIOTHERAPEUTICS : Lytix Biopharma is featured in Finansavisen, talking a..
AQ
11/11IOVANCE BIOTHERAPEUTICS : Announces Updated Phase 2 Clinical Data from the Lifil..
AQ
11/11LYTIX BIOPHARMA ANNOUNCES A CLINICAL : Iova)
AQ
11/08Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifi..
GL
11/07Iovance Biotherapeutics to Present at Upcoming Investor Conferences in Novemb..
GL
11/04IOVANCE BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Cond..
AQ
11/04IOVANCE BIOTHERAPEUTICS : 3Q Earnings Snapshot
AQ
11/04IOVANCE BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, F..
AQ
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -196 M
Net income 2019 -187 M
Finance 2019 318 M
Yield 2019 -
P/E ratio 2019 -17,4x
P/E ratio 2020 -15,8x
EV / Sales2019 infx
EV / Sales2020 114x
Capitalization 3 299 M
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IOVANCE BIOTHERAPEUTICS, I
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 35,25  $
Last Close Price 26,14  $
Spread / Highest target 130%
Spread / Average Target 34,9%
Spread / Lowest Target 14,8%
EPS Revisions
Managers
NameTitle
Maria Fardis President, Chief Executive Officer & Director
Iain D. Dukes Chairman
Timothy E. Morris Secretary, Chief Financial & Accounting Officer
Friedrich Graf Finckenstein Chief Medical Officer
Merrill A. McPeak Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IOVANCE BIOTHERAPEUTICS, INC.195.37%3 299
GUARDANT HEALTH, INC.101.92%7 127
GENSCRIPT BIOTECH CORPORATION77.52%4 475
INVITAE CORPORATION55.15%1 656
VERACYTE, INC.126.63%1 392
MIRACA HOLDINGS INC.8.31%1 374